Moreno C., Greil R., Demirkan F., Tedeschi A., Anz B., Larratt L., Simkovic M., Novak J., Strugov V., Gill D., Gribben J.G., Kwei K., Dai S., Hsu E., Dean J.P., Flinn I.W.. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. HAEMATOLOGICA. 2022; 107(9)DOI:10.3324/haematol.2021.279012. PMID:35021599. IF:10.100(Q1/2D).

Bazarbachi A., Boumendil A., Finel H., Khvedelidze I., Romejko-Jarosinska J., Tanase A., Akhtar S., Ben Othman T., Ma’koseh M., Afanasyev B., El-Cheikh J., Briones J., Gülbas Z., Hamladji R.-M., Elverdi T., Blaise D., Martínez C., Alma E., Halaburda K., Sousa A.B., Glass B., Robinson S., Montoto S., Sureda A.. Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years (Leukemia, (2022), 36, 6, (1646-1653), 10.1038/s41375-022-01563-8). LEUKEMIA. 2022; 36(8)DOI:10.1038/s41375-022-01639-5. PMID:35840758. IF:11.400(Q1/1D).

Barr P.M., Owen C., Robak T., Tedeschi A., Bairey O., Burger J.A., Hillmen P., Coutre S.E., Dearden C., Grosicki S., McCarthy H., Li J.-Y., Offner F., Moreno C., Zhou C., Hsu E., Szoke A., Kipps T.J., Ghia P.. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Advances. 2022; 6(11)DOI:10.1182/bloodadvances.2021006434. PMID:35377947. IF:7.500(Q1/2D).

Meijide J.B.. Medicina de precisión en leucemia linfática crónica: Análisis de coste-efectividad de nuevas combinaciones dirigidas. Farmacia Hospitalaria. 2022; 46(3)DOI:10.7399/fh.13280. PMID:36183201. IF:(Q/D).